Guggenheim Capital’s Cidara Therapeutics CDTX Stock Holding History

Guggenheim Capital’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,872	Closed	-$1.52M	–	1635
2025 Q4	$1.52M	Buy	+6,872	New	+$1.11M	0.01%	763
2018 Q2	–	Sell	-11,195	Closed	-$895K	–	2406
2018 Q1	$895K	Buy	11,195 +6,044	+117%	+$826K	﹤0.01%	2125
2017 Q4	$701K	Sell	5,151 -911	-15%	-$138K	﹤0.01%	2240
2017 Q3	$982K	Sell	6,062 -1,041	-15%	-$148K	﹤0.01%	2098
2017 Q2	$1.06M	Buy	+7,103	New	+$982K	﹤0.01%	2041

Guggenheim Capital's CDTX Position: Q1 2026 in Review

Guggenheim Capital sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 6,872 shares — an estimated $1.52M sold.

Guggenheim Capital first reported a position in CDTX in Q2 2017 and held it in 5 quarters. The position peaked at $1.52M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Guggenheim Capital reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Guggenheim Capital sold 6,872 Cidara Therapeutics shares in Q1 2026, an estimated $1.52M.
Guggenheim Capital first reported a position in Cidara Therapeutics in Q2 2017 and held it in 5 quarters.
Guggenheim Capital's Cidara Therapeutics position peaked at $1.52M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.